TECregen is a biotechnology company pioneering thymus rejuvenation to address conditions driven by impaired T-cell responses and immune ageing.
The company develops differentiated thymopoietic biologics that revitalize and expand thymic epithelial cells (TECs) to restore immune function, support recovery after transplantation or cytotoxic therapy, and enhance immune surveillance against cancer.
Leadership & Board
Current Number of Employees14
Current LinkedIn Followers1,495
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$10M
Total Amount Raised$10M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$10M
Latest Funding Amount$10M
Latest Funding RoundSeed Round
Latest Funding RoundSeed Round
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
TECregen had 14 employees as of September 7, 2026. The number of employees increased by 0 (0.00%) week-over-week.
14Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
TECregen had 1,495 followers as of September 7, 2026. The number of followers increased by 4 (0.27%) week-over-week.
1,495Latest Followers Count
4(0.27%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.